New combo therapy aims to slash liver cancer recurrence after surgery
NCT ID NCT07487662
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining local tumor treatments (TACE or ablation) with immunotherapy drugs (sintilimab and ipilimumab) before surgery can lower the chance of liver cancer coming back. It involves 105 adults with resectable liver cancer at intermediate-to-high risk of recurrence. The goal is to find a more effective pre-surgery regimen than surgery alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATO CELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a common anesthetic help prevent liver cancer from coming back?
- Simple gel may prevent painful side effect of liver cancer drug
- New drug shows promise for tough liver cancer cases
- New combo therapy aims to shrink advanced liver and kidney tumors
- Can a Pre-Surgery immune boost stop liver Cancer's return?
- Liver cancer trial adds a resistance-blocker to standard chemo – could it boost success?